Sage Journals: Discover world-class research

Retricted access

Review article

First published 2024-10

Lecanemab: A Humanized Monoclonal Antibody for the Treatment of Early Alzheimer Disease

Juliane Park, Carson Simpson, Katie Patel

Annals of Pharmacotherapy

Retricted access

Article commentary

First published 2023-07-18

The Anti-Amyloid Monoclonal Antibody Lecanemab: 16 Cautionary Notes

Kasper P. Kepp, Stefano L. Sensi, Kasper B. Johnsen [...]

Journal of Alzheimer’s Disease

Retricted access

Review article

First published 2025-6

Exploring the efficacy and safety of lecanemab in the management of early Alzheimer’s disease: A systematic review of clinical evidence

Rehab Emad Ashmawy, Olalekan John Okesanya, Bonaventure Michael Ukoaka [...]

Journal of Alzheimer’s Disease

Retricted access

Research article

First published 2026-2

Real-world experience with baseline characteristics and safety of lecanemab for Alzheimer's disease in Eastern China

Lumin Leng, Zhengluan Liao, Peilin Lu [...]

Journal of Alzheimer’s Disease

Open access

Research article

First published 2023-10

Novel anti-amyloid-beta (Aβ) monoclonal antibody lecanemab for Alzheimer’s disease: A systematic review

Selia Chowdhury, Nurjahan Shipa Chowdhury

International Journal of Immunopathology and Pharmacology

Retricted access

Research article

First published 2025-6

Adverse events associated with lecanemab: A disproportionality analysis of data from the FDA adverse event reporting system

Jiahao Li, Feng Zhang, Ulrich LM Eisel

Journal of Alzheimer’s Disease

Open access

Research article

First published 2024

Are There Shortages and Regional Disparities in Lecanemab Treatment Facilities? A Cross-Sectional Study

Kazuki Ohashi, Ikuko Takahashi-Iwata, Zhao Jieyu [...]

Health Services Insights

Open access

Brief report

First published 2023-06-13

Effect of Lecanemab and Donanemab in Early Alzheimer’s Disease: Mechanistic Interpretation in the Amyloid Cascade Hypothesis 2.0 Perspective

Vladimir Volloch, Sophia Rits-Volloch

Journal of Alzheimer’s Disease

Retricted access

Research article

First published 2025-2

Unveiling the safety profile of lecanemab: A comprehensive analysis of adverse events using FDA adverse event reporting system data

Wukun Ge, Yingyan Yan, Yaoyao Hu [...]

Journal of Alzheimer’s Disease

Retricted access

Research article

First published 2026-2

Comparing clinical effect sizes of Souvenaid TM,lecanemab,and donanemab in early Alzheimer’s disease

Vincenzo Solfrizzi, Bruno P Imbimbo

Journal of Alzheimer’s Disease

Search results